Keyword: Tango Therapeutics
The agreement gives Gilead the option to pick up the worldwide rights to five targets discovered and validated by Tango.
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
Allergan CFO Hilado and Gilead COO Young will retire from their positions and Rubius has poached a GSK SVP as CMO.
Tango uses CRISPR-enabled synthetic lethality to target cancer, but what really sets it apart is its paradigm-shifting approach that puts patient selection before target identification.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.
